Neuland Laboratories has announced a significant leadership transition, appointing Saharsh Davuluri as the new CEO & Managing Director, effective April 1, 2026. With over 18 years of experience at the firm, Davuluri will spearhead the company’s next phase of growth, focusing on expanding commercial contract development and manufacturing (CDMO) capabilities. The announcement comes as the company seeks to scale its complex API and peptide manufacturing footprint globally.
Strategic Leadership Transition
Neuland Laboratories has officially appointed Saharsh Davuluri as its Chief Executive Officer and Managing Director. Having served the organization for more than 18 years, Davuluri has been instrumental in the company’s transformation into a New Chemical Entity (NCE)-focused CDMO. He succeeds Sucheth Davuluri, who will transition into the role of Executive Vice Chairman to continue guiding the company’s strategic vision.
Scaling CDMO Capabilities
Under the new leadership, Neuland plans to aggressively accelerate its growth strategy over the next five years. The company has already committed to a four-phase expansion of its commercial peptide manufacturing capacity and is doubling its internal process development capabilities. These investments are designed to meet the rising demand from global biotech and big pharma partners for complex chemistries and accelerated development timelines.
Operational Footprint and Future Outlook
The company currently operates with 1,218 KL of reactor capacity across three US FDA-inspected manufacturing facilities and a 40,000 sq. ft. R&D center. With a strong track record of over 1,000 DMF filings and more than 20 active commercial contracts, Neuland is well-positioned for its next chapter. Looking ahead, the firm has expressed a clear ambition to establish itself as one of the top five API-focused CDMOs globally within the next decade.
Source: BSE
